An observational study in COVID and SARS-CoV-2, sponsored by Institute of Health Information and Statistics of the Czech Republic. Completed at 1 site in Czechia. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2020-07-01.
Sponsored by Institute of Health Information and Statistics of the Czech Republic · Observational
The aim of the SARS-CoV-2-CZ-Immunity study is to determine the time profile of the presence of antibodies against SARS-CoV-2 in blood plasma by quantification of antibodies or performing a rapid test in COVID-19 cured patients.
COVID-19 is caused by a new type of coronavirus called SARS-CoV-2. It is a highly infectious disease, manifested mainly by fever, respiratory problems, muscle pain, and fatigue. However, despite the publication of hundreds of papers in the literature, fundamental information about the spread and course of the disease is still lacking in COVID-19. One of such key information is the time profile of the presence of antibodies against SARS-CoV-2 after the disease.
The SARS-CoV-2-CZ-Immunity study is aiming at the determination of the time profile of the presence of antibodies against SARS-CoV-2 in blood plasma by quantification of antibodies or performing a rapid test in COVID-19 cured patients.
Institute of Health Information and Statistics of the Czech Republic is the lead sponsor of 14 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Both cohorts will be selected from all actually cured individuals from specific demographic areas described in the cohorts. The cohorts of people will be addressed by Public Health Office.
Inclusion Criteria:
A population cohort of cured patients based on epidemiologically defined demographic parameters - Prague and Central Bohemian Region population
Diagnostic Test: Quantitative analysis of anti-SARS-CoV-2-antibodies · Diagnostic Test: SARS-CoV-2 diagnostic rapid test
A population cohort of cured patients based on epidemiologically defined demographic parameters - South Moravian Region population.
Diagnostic Test: Quantitative analysis of anti-SARS-CoV-2-antibodies
Plasma sampling will be collected and archived for subsequent quantitative analysis of anti-SARS-CoV-2 antibodies - IgG, IgM and IgA.
The rapid test detects the presence of antibodies against SARS-CoV-2 by the immunochromatographic reaction.
Determination of the concentration of anti-SARS-CoV-2 antibodies in relation to the categories of cured patients.
The primary outcome is the determination of the concentration of anti-SARS-CoV-2 antibodies IgG, IgM, and IgA classes in relation to the categories of cured patients according to the time from the date of cure from the COVID-19 disease to the date of examination.
Time frame: May 2020
Determination of the concentration of anti-SARS-CoV-2 antibodies in relation to the age and to the severity of the disease.
The determination of the concentration of anti-SARS-CoV-2 antibodies IgG, IgM, and IgA classes in relation to the categories of cured patients according to their age: category 8-17, 18-39, 40-59, 60 and more years and according to the severity of the disease.
Time frame: June 2020
The quantification of the dependence of the change in the concentration of anti-SARS-CoV-2 antibodies.
The quantification of the dependence of the change in the concentration of anti-SARS-CoV-2 antibodies IgG, IgM, and IgA classes on the time since cure (analysis by statistical model)
Time frame: June 2020
The identification of potential donors of convalescent plasma.
The identification of individuals in the study population, who can be contacted as voluntary donors of convalescent plasma, which is one of the therapeutic modalities in patients with severe COVID-19 disease.
Time frame: June2020
Plan to share: Undecided — It is not yet known if there will be a plan to make IPD available.
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute of Health Information and Statistics of the Czech Republic